Outcome measures for assessing change over time in studies of symptomatic children with hypermobility: a systematic review

Muhammad Maarj (✉ Muhammad.Maarj@uon.edu.au)
The University of Newcastle - Central Coast Campus https://orcid.org/0000-0003-4002-3664

Andrea Coda
The University of Newcastle - Central Coast Campus

Louise Tofts
Macquarie University

Cylie Williams
Monash University Faculty of Medicine Nursing and Health Sciences

Derek Santos
Queen Margaret University Edinburgh

Verity Pacey
Macquarie University

Research article

Keywords: Fatigue; Outcome measures; Paediatrics; Hypermobility; Pain; Function; Quality of Life

DOI: https://doi.org/10.21203/rs.3.rs-60935/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

This study aimed to synthesise outcome measure type and use in interventional or prospective longitudinal studies of children with generalised joint hypermobility (GJH) and associated symptoms.

Method

Electronic searches of Medline, CINAHL and Embase databases from inception to 16th March 2020 were performed for studies of children with GJH and symptoms between 5-18 years reporting repeated outcome measures collected at least 4 weeks apart. Methodological quality of eligible studies were described using the Downs and Black checklist.

Results

Six studies comprising of five interventional, and one prospective observational study (total of 388 children) met the inclusion criteria. Intervventional study durations were between 2 to 3 months, with up to 10 months post-intervention follow-up, while the observational study spanned 3 years. Three main constructs of pain, function and quality of life were reported as primary outcome measures using 20 different instruments. All but one measure was validated in paediatric populations, but not specifically for children with GJH and symptoms. One study assessed fatigue, reporting disabling fatigue to be associated with higher pain intensity.

Conclusions

There were no agreed sets of outcome measures for children with GJH and symptoms found. The standardisation of assessment tools across paediatric clinical trials is needed. Four constructs of pain, function, quality of life and fatigue are recommended to be included with agreed upon, validated, objective tools.

Background

Children with generalised joint hypermobility (GJH) and associated symptoms have been described within the literature under multiple diagnostic labels which have differed over time. Generalised joint hypermobility (GJH) describes abnormally high joint ranges of movement in multiple joints (1) and presents in 20–40% of the paediatric population (2, 3) with approximately one-fifth of children with GJH reporting symptoms (3, 4). Currently used diagnostic labels describing children with GJH with associated symptoms include Generalised Hypermobility Spectrum Disorder (G-HSD) (5), and hypermobile Ehlers-Danlos Syndrome (hEDS), which further incorporates an extended phenotype including skin involvement, tissue fragility or a marfanoid body habitus (6). These conditions were previously referred to as Joint Hypermobility Syndrome (JHS) or EDS-Hypermobile type, with experts reporting a lack of clinical distinction between the two (7, 8). The Term “Children with GJH and associated symptoms” will be used throughout this review to indicate any of the current or previously used terminology for this condition.

Children with GJH and associated symptoms report chronic pain (9), fatigue (10) and functional difficulties (11) that have a negative impact on their quality of life (12, 13). Chronic joint pain is often exacerbated following physical activity (14) with lower limb pain being the most common location described (15). Joint instability episodes and frequent soft tissue injuries have also been reported (15). Functional difficulties reported include motor development challenges (16), muscle torque deficits and poor proprioception (17) resulting in a negative influence on school and/or social activity participation (18). Children with GJH also describe systemic symptoms including orthostatic intolerance, functional gastrointestinal disorders and stress incontinence (12, 15), a greater number of systemic symptoms leads to worse functional disability (19). Additional psychological symptoms may also result in poorer quality of life than typically developing children (13, 15, 20, 21).

Validated, reliable outcome measures aid evaluation of treatment effectiveness. Despite the importance of such validated outcome measures in paediatric populations (22) there are no condition specific outcome measurement instruments for children with GJH and associated symptoms. Consequently, recent systematic reviews and meta-analyses have been largely inconclusive, partially due to the lack of standardised outcome measures used between studies (23–26). Therefore, this study aimed to synthesise outcome measure type and use in interventional or prospective longitudinal studies of children with GJH and associated symptoms.

Methods

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (27). The protocol was registered on the Prospective Register of Systematic Reviews (PROSPERO) database (registration number CRD 42018081835) prior to commencement of database searches.

Search Strategy

Medline (via PubMed), CINAHL and Embase databases were searched from inception to 16th March 2020 using the terms and strategy presented in Table 1. Further studies were retrieved from backward manual searches of references lists of included studies. There was no restriction imposed by publication year or language.
Table 1
Search terms and search strategy documentation for PubMed†

1. Paediatric* OR Pediatric*
2. Child* OR Juvenile* OR Adolescent*
3. #1 OR #2
4. Measure* OR Therap* OR Outcome* OR Hypermob*
5. #3 AND #4
6. Elhers* OR Double-Join* OR Brighton OR Beighton OR Beighton
7. # 5 AND #6

†This search strategy was modified for CINAHL and Embase databases.

Notes. *=truncate; tw: text word

2.2 Eligibility Criteria
Randomised controlled trials (RCTs), quasi-RCTs, longitudinal and cohort studies were included. The study populations were restricted to children and adolescents aged between 5–18 years, diagnosed with GJH and associated symptoms. Included studies were required to describe outcome measures utilised at least 4 weeks apart in order to identify change over time.

Studies focusing on upper limb only outcome measures, or studies including children with other hereditary connective tissue disorders or syndromic conditions associated with GJH, were not included.

Study selection
Titles, abstracts and full-text article screening was performed independently by two authors (MM and AC) against the inclusion/exclusion criteria. Any discrepancies were resolved either by discussion between the two reviewers or by a third author (DS) until consensus was reached.

Data extraction
Two reviewers (MM and CW) independently extracted relevant data from included full text articles. Data extraction was performed on a standardised template and included: the primary author of the study, year of publication, country, study design, participant demographics (sample size, gender and age), intervention characteristics (type, duration and follow-up) where applicable, and outcome measures used to assess change. Any unresolved disagreements were mediated by the remaining authors (AC, LT, DS and VP).

Risk of bias assessment
The methodological quality of all eligible studies was reviewed independently by two authors (MM and DS) using the Downs and Black checklist. Any disagreements were discussed until a consensus was reached or resolved by a third author (AC). The Downs and Black checklist (28) is a validated methodological quality assessment tool covering 5 domains of reporting, external quality, internal validity (bias), internal validity confounding or selection bias, and statistical power (29).

Data analysis
Descriptive statistics were used to characterise the included studies participant population, duration and intervention. Outcome measures used were categorised into patient-reported or parent-reported (PRO) or clinician-reported (CRO) outcomes, and the broad constructs which were being assessed. The frequency of individual outcome measures used to assess each construct was then tallied. A narrative synthesis of the outcome measures used across study type and participant age was performed, including presentation of the baseline scores on measures. To provide a description of the change over time, the mean change, and variance in this, was also presented. Where 95% CIs were not presented to represent the variance in change, they were calculated.

Results
Selection strategy and methodological appraisal
From a total of 1136 articles identified through the searches, 57 articles were deemed eligible for full-text screening with six studies eligible to be included in this review (Fig. 1). Five interventional studies were identified, these were four randomised controlled trials (RCTs) and one pre-post cohort study. The sixth was a prospective observational study. All included studies were published during the last ten years.
The methodological quality of the six studies was described in Table 2. Main limitations of the studies included poor description of principal confounders, lack of participant blinding, not reporting adverse events related to intervention(s), and not minimising bias for data collection. The strength of included studies were clearly described main outcomes, recruitment of participants from the same target population as well as the use of validated and reliable outcome measures appropriate for the general paediatric population. While all interventional studies clearly described the trial and control interventions, only one study blinded participants to the interventions while the other four studies demonstrated blinding of assessors to the group allocation of intervention or controls.

Table 2
Assessment of methodological quality of eligible studies using Downs & Black checklist (Downs and Black 1998)\textsuperscript{a}

| Items | Criteria | Bale (2019) | Hsieh (2018) | Revivo (2018) | Pacey (2013) | Kemp (2010) | Scheper (2017) |
|-------|----------|-------------|--------------|---------------|--------------|-------------|---------------|
| 1     | Study hypothesis/aim/objective clearly described | 1 | 1 | 1 | 1 | 1 | 0 |
| 2     | Main outcomes in Introduction or Methods section | 1 | 1 | 1 | 1 | 1 | 1 |
| 3     | Patient characteristics clearly described | 1 | 1 | 1 | 1 | 1 | 1 |
| 4     | Relevant interventions including controls clearly described | 1 | 1 | 1 | 1 | 1 | NA |
| 5     | Distributions of principal confounders clearly described | 0 | 0 | 1 | 0 | 0 | 2 |
| 6     | Main findings (including outcomes) clearly described | 1 | 1 | 1 | 1 | 1 | 1 |
| 7     | Estimates of random variability in data for the main outcomes provided | 1 | 1 | 1 | 1 | 1 | 1 |
| 8     | All important adverse events related to intervention(s) reported | 0 | 0 | 0 | 1 | 0 | NA |
| 9     | Patient characteristics lost to follow-up described | 1 | 1 | 1 | 1 | 0 | 0 |
| 10    | Actual probability values for main outcomes reported | 1 | 1 | 1 | 1 | 1 | 1 |

EXTERNAL VALIDITY

| Items | Criteria | Bale (2019) | Hsieh (2018) | Revivo (2018) | Pacey (2013) | Kemp (2010) | Scheper (2017) |
|-------|----------|-------------|--------------|---------------|--------------|-------------|---------------|
| 11    | Subjects asked to participate were representative of target populations | 1 | 1 | 1 | 1 | 1 | 1 |
| 12    | Subjects prepared to participate were representative of target populations | 1 | 1 | 1 | 1 | 1 | 1 |
| 13    | Treatment facilities and delivery were representative of target populations | 1 | 1 | 1 | 1 | 1 | 1 |
| Items | Criteria | Bale (2019) | Hsieh (2018) | Revivo (2019) | Pacey (2013) | Kemp (2010) | Scheper (2017) |
|-------|----------|-------------|--------------|--------------|--------------|-------------|---------------|
| 14    | Study participants blinded to intervention administered | 0 | 0 | 0 | 1 | 0 | NA |
| 15    | Investigators blinded to assessment of main intervention outcomes | 1 | 1 | 0 | 1 | 1 | NA |
| 16    | Any data dredging was made clear at onset of study | 0 | 0 | 1 | 1 | 1 | 0 |
| 17    | Analyses adjust for different lengths of follow-up of participants | 1 | 0 | 1 | 1 | 0 | 1 |
| 18    | Statistical tests to assess the main outcomes were appropriate | 1 | 1 | 1 | 1 | 1 | 1 |
| 19    | Reliability of compliance with intervention(s) | 1 | 1 | 1 | 1 | 0 | NA |
| 20    | Main outcome measures used accurate in terms of validity and reliability. | 1 | 1 | 1 | 1 | 1 | 1 |
|       | **INTERNAL VALIDITY - confounding (selection bias)** | | | | | | |
| 21    | All participants were recruited from the same target population | 1 | 1 | 1 | 1 | 1 | 1 |
| 22    | All participants were recruited over the same period of time | 1 | 1 | 0 | 1 | 1 | 1 |
| 23    | Participants were randomised to intervention group(s) | 1 | 1 | 0 | 1 | 1 | NA |
| 24    | Randomised intervention assignment was concealed from both participants and investigators | 0 | 0 | 0 | 1 | 0 | NA |
| 25    | Adequate adjustment for confounding | 0 | 0 | 0 | 0 | 0 | 1 |
| 26    | Lost to follow-up considered | 1 | 0 | 1 | 1 | 0 | 0 |
| 27    | Statistical power-clinical meaningful effect or power calculation reported b | \(1^-\) | 1 | 1 | 1 | 1 | 1 |

*Power calculation reported but not clinically meaningful*

*The scoring given for each criteria was 1 point for 'Yes' or 0 point for 'No' except question 5 which is scored as 2 for 'Yes', 1 for partially or 0 for 'No' related to the distribution of principle confounders (28). For observational study NA = Not applicable.*

*b Only one point was awarded to an interventional study powered to detect a meaningful clinical effect (49, 50).*

**Characteristics of the eligible studies**

The main characteristics of included studies are summarised in Table 3. There were 388 participants in total from the six studies. Overall, studies included primarily female participants, and ranged in duration from 2 months to 3 years. Interventions included either exercise therapy alone (n = 3) or combined with orthotics (n = 1) or multidisciplinary (n = 2). All participants were recruited from children's hospital clinics.
### Table 3
Characteristics of eligible studies included in this systematic review

| Study (year) Country | Study Design | Participant characteristics | Outcome assessment |
|----------------------|-------------|----------------------------|--------------------|
| **Bale et al. (2019)** | Randomised controlled trial | | |
| UK | | | |
| | | Participants (n) | Drop out (%) | Age in years Mean (SD) | Beighton score Mean (SD) | Recruitment site | Treatment or intervention group | Control group | Duration (Follow-up $^\S$) |
| | | 119 baseline | 7% | 9.4 (3.2) | 5.7 (1.4) | Children's department at tertiary Hospital | therapy intervention (Tertiary PT and OT x5 sessions) | Standard care (medical assessment and allied health referrals) | 2 months (1, 10 months) |
| | | 111 At 3 months | 12% | 55% | | | | | |
| | | 105 At 12 months | | | | | | | |
| **Hsieh et al. (2018)** | Randomised controlled trial | | |
| Taiwan | | | |
| | | 52 Baseline | 4% | 6.6 (0.6) | 7.5 (1.6) | Outpatient rehabilitation center – teaching hospital | Physical therapy & orthotics with customised insoles | Physical therapy & podiatry without customised insoles | 3 months |
| | | 50 At 3 months | | 46% | | | | | |
| **Kemp et al. (2010)** | Randomised controlled trial | | |
| UK | | | |
| | | 57 Baseline | 44% | 10.9 (2.5) | 5.8 (1.6) | Rheumatology Outpatient department | Psychosocial & physical therapy targeted to improve functional stability of symptomatic joints | Generalised therapy to improve muscle strength & fitness | 2 months (3 months follow-up) |
| | | 32 At 3 months | 33% | | | | | |
| Study (year) | Study Design | Participant characteristics | Outcome assessment |
|-------------|--------------|----------------------------|--------------------|
| **Pacey et al. (2013)** | Randomised controlled trial | 29 participants | Physiotherapy department in a teaching hospital |
| | | (Baseline 26, randomised 25) | Physical therapy: Muscle strength & motion control performed into full range of knee hyperextension |
| | | 2 months | Physical therapy: Muscle strength & motion control performed into knee extension neutral range |
| | | | 14% Drop out | 2 months baseline without treatment followed by 8 treatment sessions and home exercises over 2 months |
| | | | Age in years Mean (SD) 12.1 (2.9) 66% |
| | | | Beighton score Mean (SD) 7.1 (1.2) |
| | | | Recruitment site |
| **Revivo et al. (2019)** | Pre-Post retrospective | 30 participants | Hospital Outpatient multidisciplinary pain management clinic |
| | | (Baseline 26) | Physical therapy, occupational therapy, psychology counselling, & weekly paediatric rehabilitation follow-up |
| | | 2 months | None |
| | | | 13% Drop out | 1.5-2 months |
| | | | Age in years Mean (SD) 14.0 (2.8) 90% |
| | | | Beighton score Mean (SD) > 4 |
| | | | Recruitment site |
| **Scheper et al. (2017)** | Observational longitudinal | 101 participants | Tertiary hospital Outpatients clinics |
| | | (Baseline 81) | No restrictions on treatment of participants |
| | | 3 years | None |
| | | | % Female |
| **†** Based on a 9 point scale (51). The score is combined for both treated and control. |
| **§** Follow-up is post-intervention |

**Outcome measures**

Table 4 provides descriptions of the outcome measures and instruments used in the studies where the change in these measures over time was able to be collected or provided by the authors. There were 20 distinct outcome instruments measuring the four constructs of pain (30–34), function (30–35), quality of life (30–34) and fatigue (32) which included 15 PROs (7 patient-reported and 8 parent-reported) and 4 CROs. All PRO instruments except one (PGIC: Patient’s Global Impression of Change) (33) have been validated for use in the paediatric population. Pain was the most common construct measured, using 4 different PROs (30, 32–35), the patient-reported VAS (Visual Analogue Scale) (30, 32–34), parent-reported VAS (30, 34), NRS (Numerical Rating Scale) (35), and the WBFPS (Wong-Baker Faces Pain Scale) (30).
Table 4
Outcome measures categorised according to pain, function, quality of life and fatigue.

| Outcome measures                      | Follow-up Timeframe | Baseline | Mean change in outcome at follow-up | 95% CI |
|---------------------------------------|---------------------|----------|-------------------------------------|-------|
| Scale                                 | Test details        | Type     |                                    |       |
| PAIN (Intensity)                      |                     |          |                                     |       |
| VAS (52, 53)                          |                     | PRO      | 2 months (33)                       |       |
| Visual Analogue scale                 | 0-100               | Neutral treatment group: 40.0 (16.6) | -19.9 | NR                               |
|                                       | 0 = no pain         | Hypermobility treatment group: 38.6 (16.9) | -9.19 | NR                               |
|                                       | 100 = worst pain    | Combined groups: 39.4 (14.2)             | -14.5 | -5.2, -23.8                      |
|                                       |                     | 5 months | Targeted Physiotherapy: 55.5 (21.3) | -21.2 | -38, -4.5                        |
| (Wong-baker faces pain scale)         | 0-5                 | General Physiotherapy: 62.1 (24.1)       | -30.6 | -50.16, -11.0                    |
|                                       | 0 = no pain         | Combined groups: 57.6 (20.1)             | -25.8 | -38.5, -13.1                     |
|                                       | 5 = worst pain      |          |                                     |       |
| WBFPS (54, 55)                         |                     | PRO      | 12 months (30)                      |       |
| (Wong-baker faces pain scale)         | 0-5                 | Intervention: 2.2 (1.4)                  | -1.6  | -2.1, -1.1                       |
|                                       | 0 = no pain         | Control: 2.5 (1.6)                       | -1.6  | -2.0, -1.2                       |
|                                       | 5 = worst pain      |          |                                     |       |

When considering all the PROs used, the patient-reported VAS (30, 32–34), CHAQ (Childhood Health Assessment Questionnaire) (30, 32–34) and parent-reported VAS (30, 34) were the only PRO measures used in more than one study.

Function was assessed with a total of nine different assessment tools. Five PROs were used to assess function including the CHAQ (30, 33, 34), PODCI (Pediatric Outcomes Data Collection Instrument) (31), and the BAPQ 61 (Bath Adolescent Pain questionnaire) (35). The BAP-PIQ (Parent Impact Questionnaire) was also used to assess the impact of the child's condition on the parents daily function (35), and the APARQ (Adolescent Physical Activity Recall Questionnaire) scale to assess a child's physical activity (32). The 4 CROs used to assess function included the 6 minute walking test to assess walking endurance (32), the ability to climb stairs in a set time (33), the Movement ABC2 (Assessment Battery for Children, 2nd Edition) (30) to assess gross motor skills, and muscle strength (30, 33). Strength was measured in two studies, however they each assessed different muscle groups (30, 33).

Quality of life was described using the three different patient-reported outcome scales CHU9D (Child Health Utility 9D) (30), PGIC (33) and PedsQL (Pediatrics Quality of life) (32). The change in the child's quality of life reported by parents was measured using PODCI (31), CHQ-PF50.
Discussion

There was significant heterogeneity in the use of instruments across studies included within this systematic review. Multiple studies measured pain intensity, function and quality of life constructs; however, fatigue was measured in only one study, which found it to be an independent predictor of functional deterioration. All measures used demonstrated change over time.

The identified PRO measures used similar item sets without taking into account lifestyle or severity of the condition. This limits their translational capabilities into clinical practice. Despite the advantage of assessing the same outcome repeatedly in a clinical trial for research, measuring changes in symptoms tailored to the child's individual presentation may be more beneficial to inform clinical decisions (36). Children with GJH and associated symptoms commonly describe variable symptoms depending on their lifestyles, environmental conditions or individual characteristics (37). The use of PROs with more inclusive questions that capture all relevant domains to an individual and their specific condition may provide a more useful alternative to better assist clinicians translate evidence into practice. Furthermore, the use of measures specifically validated for children with GJH and associated symptoms, would provide more robust evidence for the effectiveness of interventions in this patient population.

Therapy aims to improve quality of life and reduce disability in children with GJH and associated symptoms (38). It is unknown if generic outcome measures alone would enable reporting with adequate validity and sensitivity (39, 40). In this present review, the majority of studies administered multiple instruments, combining both PRO and CRO scales. Further evaluation with qualitative methodology may provide valuable insight into the priorities and needs of children with GJH and associated symptoms, and their caregivers. This may refine the constructs and specific outcome measures used in future research and clinical practice.

Consistent use of measures across studies of children with GJH and associated symptoms, ideally with a clear diagnostic label, would allow for informed assessment of therapy effectiveness. Lack of standardisation, together with the limited number of interventional or prospective cohort studies, has hampered quantitative synthesis of efficacy of interventions using meta-analysis in previous systematic reviews (23, 24). In other paediatric rheumatological health conditions, such as Juvenile Idiopathic Arthritis (JIA), established and revised core sets of outcomes determined through expert health professional consensus (41, 42) have been used. In line with the findings of our review, the JIA international workgroup prioritised pain, function and quality of life (overall wellbeing) as mandatory domains for research. In addition, fatigue prioritised by patient/parents was considered an important construct outcome measure for inclusion in the most recent update (42).

There is a substantial impact of fatigue on quality of life of children with GJH and associated symptoms (15, 19, 20, 43, 44). The most poorly functioning children diagnosed with hypermobility and associated symptoms experience worse fatigue and higher pain intensity than their peers (32). No single assessment instrument has been identified to measure the severity of fatigue and its impact on wellbeing in this population group. Given the significance of fatigue, strong consideration of fatigue measurement is recommended within a core set of outcome measures.

Studies have also reported children and parents describing systemic symptoms such as gastrointestinal involvement and stress incontinence associated with poorer quality of life relating to hypermobility (15, 45, 46). Outcome measures that identify the impact of different systemic symptoms on child function and quality of life may also be useful to guide clinical management and assess the efficacy of interventions in this population.

This review was strengthened through the registration of a protocol, adherence to established PRISMA guidelines, and appraisal of methodological quality using a tool with substantial inter-rater reliability (47), and one that highlighted for use in assessing the quality of non-randomised controlled studies (48). We acknowledge a number of limitations to this review. The research strategy used within this review only identified studies published in English despite no language restrictions placed on eligibility criteria. Additionally, it was not the aim of the review to assess the validity or reliability of the included measures in the paediatric or condition-specific population.

Conclusions

An agreed set of core outcome measures for children with GJH and associated symptoms is warranted. More precisely defined diagnostic criteria for children with hypermobility related disorders, in conjunction with standardised reporting of the effectiveness of interventions using similar outcome measures in future studies will produce better quality evidence to facilitate translation into healthcare services. We recommend the development of a core set of outcome measures based around the four constructs of pain, function, quality of life and fatigue. Mixed methodology, including the views of children living with GJH and associated symptoms and their families on what is important to them,
combined with expert consensus, validation of generic outcome measures in this population and development of condition specific outcome measures, would provide the ideal final core outcome set for future use.

**List Of Abbreviations**

ABC2 - Assessment Battery for Children, 2nd Edition

APARQ - Adolescent Physical Activity Recall Questionnaire

BAPQ - Bath Adolescent Pain questionnaire

CHAQ - Childhood Health Assessment Questionnaire

CHQ-PF50 - Child Health Questionnaire

CHU9D - Child Health Utility 9D

CINAHL - Cumulative Index of Nursing and Allied Health Literature

CRO - Clinician reported outcome

G-HSD - Generalised Hypermobility Spectrum Disorder

GJH - Generalised joint hypermobility

hEDS - hypermobile Ehlers-Danlos Syndrome

JHS - Joint Hypermobility Syndrome

JIA - Juvenile Idiopathic Arthritis

NRS - Numerical Rating Scale

PedsQL - Pediatrics Quality of life

PGIC - Patient's Global Impression of Change

PODCI - Pediatric Outcomes Data Collection Instrument

PRISMA - Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PRO - Patient reported or Parent reported outcome

PROSPERO - Prospective Register of Systematic Reviews

RCT - Randomised controlled trials

VAS - Visual Analogue Scale

WBFPS - Wong-Baker Faces Pain Scale

**Declarations**

**Ethics approval and consent to participate**

Waived

**Consent for publication**

All authors consent for publication

**Availability of data and materials**

Not applicable, systematic review.
Competing interests

The authors declare that they have no competing interests

Funding

Muhammad Maarj is supported by University of Newcastle under a government funded position (Research Training Program fee offset scholarship).

Authors’ contributions

MM and AC designed and conceptualised the systematic review, performed the search and screening; MM and CW extracted the data; MM and DC performed the risk of bias assessment. MM and VP drafted and revised the manuscript. AC and LT served as second reviewer for the systematic review and revised the manuscript. All authors have read and approved the final manuscript.

Acknowledgements

None.

References

1. Kirk J, Ansell B, Bywaters E. The hypermobility syndrome. Musculoskeletal complaints associated with generalized joint hypermobility. Annals of the Rheumatic Diseases. 1967;26(5):419.
2. Clinch J, Deere K, Sayers A, Palmer S, Riddoch C, Tobias JH, et al. Epidemiology of generalized joint laxity (hypermobility) in fourteen-year-old children from the UK: a population-based evaluation. Arthritis and rheumatism. 2011;63(9):2819-27.
3. Remvig L, Kümmel C, Kristensen JH, Boas G, Juul-Kristensen B. Prevalence of generalized joint hypermobility, arthralgia and motor competence in 10-year-old school children. International Musculoskeletal Medicine. 2011;33(4):137-45.
4. Sperotto F, Balzarini M, Parolin M, Monteforte N, Vittadello F, Zulian F. Joint hypermobility, growing pain and obesity are mutually exclusive as causes of musculoskeletal pain in schoolchildren. Clinical and experimental rheumatology. 2014;32(1):131-6.
5. Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A, editors. A framework for the classification of joint hypermobility and related conditions. American Journal of Medical Genetics Part C: Seminars in Medical Genetics; 2017: Wiley Online Library.
6. Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al., editors. The 2017 international classification of the Ehlers–Danlos syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics; 2017: Wiley Online Library.
7. Tofts LJ, Elliott EJ, Munns C, Pacey V, Silence DO. The differential diagnosis of children with joint hypermobility: a review of the literature. Pediatric Rheumatology. 2009;7(1):1.
8. Tinkle BT, Bird HA, Grahame R, Lavallee M, Levy HP, Silence D. The lack of clinical distinction between the hypermobility type of Ehlers–Danlos syndrome and the joint hypermobility syndrome (aka hypermobility syndrome). American journal of medical genetics part A. 2009;149(11):2368-70.
9. Grahame R. Hypermobility: an important but often neglected area within rheumatology. Nature clinical practice Rheumatology. 2008;4(10):522-4.
10. Voermans NC, Knoop H, Bleijenberg G, van Engelen BG. Fatigue is associated with muscle weakness in Ehlers-Danlos syndrome: an explorative study. Physiotherapy. 2011;97(2):170-4.
11. Hanewinkel-van Kleef YB, Helders PJ, Takken T, Engelbert RH. Motor performance in children with generalized hypermobility: the influence of muscle strength and exercise capacity. Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association. 2009;21(2):194-200.
12. Fatoye F, Palmer S, Macmillan F, Rowe P, van der Linden M. Pain intensity and quality of life perception in children with hypermobility syndrome. Rheumatology international. 2012;32(5):1277-84.
13. Mu W, Muriello M, Clemens JL, Wang Y, Smith CH, Tran PT, et al. Factors affecting quality of life in children and adolescents with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders. American Journal of Medical Genetics Part A. 2019;179(4):561-9.
14. Armon K. Musculoskeletal pain and hypermobility in children and young people: is it benign joint hypermobility syndrome? : BMJ Publishing Group Ltd; 2015.
15. Pacey V, Tofts L, Adams R, Nicholson L. Factors affecting change in children with joint hypermobility syndrome: Results of a prospective longitudinal study. Internal Medicine Journal. 2015;45:9.
16. Engelbert RH, Kooijmans FT, van Riet AM, Feitsma TM, Uiterwaal CS, Helders PJ. The relationship between generalized joint hypermobility and motor development. Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy
17. Fatoye F, Palmer S, Macmillan F, Rowe P, van der Linden M. Proprioception and muscle torque deficits in children with hypermobility syndrome. Rheumatology (Oxford, England). 2009;48(2):152-7.
18. Schubert-Hjalmarsson E, Öhman A, Kyllerman M, Beckung E. Pain, balance, activity, and participation in children with hypermobility syndrome. Pediatric Physical Therapy. 2012;24(4):339-44.
19. Scheppe MC, Juul-Kristensen B, Rombaut L, Rameckers EA, Verbunt J, Engelbert RH. Disability in Adolescents and Adults Diagnosed With Hypermobility-Related Disorders: A Meta-Analysis. Archives of Physical Medicine and Rehabilitation. 2016;97(12):2174-87.
20. Zekry OA, Ahmed MA, Elwahid HAEA. The impact of fatigue on health related quality of life in adolescents with benign joint hypermobility syndrome. The Egyptian Rheumatologist. 2013;35(2):77-85.
21. Baeza-Velasco C, Gély-Nargeot M, Vilarrasa AB, Bravo J. Joint hypermobility syndrome: problems that require psychological intervention. Rheumatology international. 2011;31(9):1131-6.
22. Rome K, Ashford RL, Evans A. Non-surgical interventions for paediatric pes planus. Cochrane Database of systematic reviews. 2010(7).
23. Scheppe MC, Engelbert RHH, Rameckers EAA, Verbunt J, Remvig L, Juul-Kristensen B. Children with generalised joint hypermobility and musculoskeletal complaints: state of the art on diagnostics, clinical characteristics, and treatment. BioMed Research International. 2013;2013:121054-.
24. Peterson B, Coda A, Pacey V, Hawke F. Physical and mechanical therapies for lower limb symptoms in children with Hypermobility Spectrum Disorder and Hypermobile Ehlers-Danlos Syndrome: a systematic review. Journal of foot and ankle research. 2018;11:59.
25. Engelbert RHH, Scheppe M, Rameckers E, Verbunt J, Remvig L, Juul-Kristensen B. Children with generalized joint hypermobility and musculoskeletal complaints: State of the art on diagnostics, clinical characteristics and treatment. Annals of the Rheumatic Diseases. 2013;72.
26. Smith TO, Bacon H, Jerman E, Easton V, Armon K, Poland F, et al. Physiotherapy and occupational therapy interventions for people with benign joint hypermobility syndrome: a systematic review of clinical trials. Disability and rehabilitation. 2014;36(10):797-803.
27. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical research ed). 2010;340:c869.
28. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology & Community Health. 1998;52(6):377-84.
29. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health technology assessment (Winchester, England). 2003;7(27):iii-x, 1-173.
30. Bale P, Easton V, Bacon H, Jerman E, Watts L, Barton G, et al. The effectiveness of a multidisciplinary intervention strategy for the treatment of symptomatic joint hypermobility in childhood: a randomised, single Centre parallel group trial (The Bendy Study). Pediatric rheumatology online journal. 2019;17(1):2.
31. Hsieh RL, Peng HL, Lee WC. Short-term effects of customized arch support insoles on symptomatic flexible flatfoot in children: A randomized controlled trial. Medicine. 2018;97(20):e10655.
32. Scheppe MC, Nicholson LL, Adams RD, Tofts L, Pacey V. The natural history of children with joint hypermobility syndrome and Ehlers-Danlos hypermobility type: a longitudinal cohort study. Rheumatology (Oxford, England). 2017;56(12):2073-83.
33. Pacey V, Tofts L, Adams RD, Munns CF, Nicholson LL. Exercise in children with joint hypermobility syndrome and knee pain: a randomised controlled trial comparing exercise versus a neutral knee extension. Pediatric rheumatology online journal. 2013;11(1):30.
34. Kemp S, Roberts I, Gamble C, Wilkinson S, Davidson JE, Baildam EM, et al. A randomized comparative trial of generalized vs targeted physiotherapy in the management of childhood hypermobility. Rheumatology (Oxford, England). 2010;49(2):315-25.
35. Revivo G, Amstutz DK, Gagnon CM, McCormick ZL. Interdisciplinary Pain Management Improves Pain and Function in Pediatric Patients with Chronic Pain Associated with Joint Hypermobility Syndrome. PM & R: the journal of injury, function, and rehabilitation. 2011;3(2):150-7.
36. Bilsbury CD, Richman A. A staging approach to measuring patient-centred subjective outcomes. Acta psychiatraca Scandinavica. 2002;106:5-40.
37. Kumar B, Lenert P. Joint hypermobility syndrome: recognizing a commonly overlooked cause of chronic pain. The American journal of medicine. 2017;130(6):640-7.
38. Engelbert RHH, Juul-Kristensen B, Pacey V, de Wandele I, Smeenk S, Woinarosky N, et al. The evidence-based rationale for physical therapy treatment of children, adolescents, and adults diagnosed with joint hypermobility syndrome/hypermobile Ehlers Danlos syndrome. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics. 2017;175(1):158-67.
39. Brinker MR, O’Connor DP. Stakeholders in outcome measures: review from a clinical perspective. Clinical orthopaedics and related research. 2013;471(11):3426-36.
40. Fayers P, Machin D. Item response theory and differential item functioning. Quality of Life the Assessment, Analysis and Interpretation of Patient-Reported Outcomes, 2nd ed Chichester: Wiley. 2007:161-88.

41. Morgan EM, Rieschelger MP, Hronjeff J, Consolaro A, Munro JE, Thornhill S, et al. Evidence for updating the core domain set of outcome measures for juvenile idiopathic arthritis: report from a special interest group at OMERACT 2016. The Journal of rheumatology. 2017;44(12):1884-8.

42. Morgan EM, Munro JE, Hronjeff J, Horgan B, Shea B, Feldman BM, et al. Establishing an updated core domain set for studies in juvenile idiopathic arthritis: a report from the OMERACT 2018 JIA Workshop. The Journal of rheumatology. 2019;46(8):1006-13.

43. Mu W, Muriello M, Clemens JL, Wang Y, Smith CH, Tran PT, et al. Factors affecting quality of life in children and adolescents with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders. American Journal of Medical Genetics Part A. 2019;179(4):561-9.

44. Castori M, Celletti C, Camerota F, Grammatico P. Chronic fatigue syndrome is commonly diagnosed in patients with Ehlers-Danlos syndrome hypermobility type/joint hypermobility syndrome. Clinical and Experimental Rheumatology-Incl Supplements. 2011;29(3):597.

45. Castori M, Speruditi I, Celletti C, Camerota F, Grammatico P. Symptom and joint mobility progression in the joint hypermobility syndrome (Ehlers-Danlos syndrome, hypermobility type). Clinical and experimental rheumatology. 2011;29(6):998-1005.

46. Di Mattia F, Fary R, Murray KJ, Howie E, Smith A, Morris S. Two subtypes of symptomatic joint hypermobility: a descriptive study using latent class analysis. Archives of Disease in Childhood. 2019;104(11):1099-101.

47. O’Connor SR, Tully MA, Ryan B, Bradley JM, Baxter GD, McDonough SM. Failure of a numerical quality assessment scale to identify potential risk of bias in a systematic review: a comparison study. BMC research notes. 2015;8(1):224.

48. Higgins JP, green S. Cochrane handbook for systematic reviews of interventions version. 2011;5(0):3.

49. Theis J, Gerdhem P, Abbott A. Quality of life outcomes in surgically treated adult scoliosis patients: a systematic review. European spine journal. 2015;24(7):1343-55.

50. Chudyk AM, Jutai JW, Petrella RJ, Speechley M. Systematic review of hip fracture rehabilitation practices in the elderly. Archives of physical medicine and rehabilitation. 2009;90(2):246-62.

51. Beighton P, Solomon L, Soskolne C. Articular mobility in an African population. Annals of the rheumatic diseases. 1973;32(5):413.

52. Shields B, Palermo T, Powers J, Grewe S, Smith G. Predictors of a child's ability to use a visual analogue scale. Child: care, health and development. 2003;29(4):281-90.

53. Crossley KM, Bennell KL, Cowan SM, Green S. Analysis of outcome measures for persons with patellofemoral pain: which are reliable and valid? Archives of physical medicine and rehabilitation. 2004;85(5):815-22.

54. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs. 1988;14(1):9-17.

55. Garra G, Singer AJ, Taira BR, Chohan J, Cardoz H, Chisena E, et al. Validation of the Wong-Baker FACES pain rating scale in pediatric emergency department patients. Academic Emergency Medicine. 2010;17(1):50-4.

56. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. The Journal of rheumatology. 2010;37(7):1534-41.

57. Nugent J, Ruperto N, Grainger J, Machado C, Sawhney S, Baildam E, et al. The British version of the childhood health assessment questionnaire (CHAQ) and the child health questionnaire (CHQ). Clinical and experimental rheumatology. 2001;19(4; SUPP/23):S163-S7.

58. Hébert LJ, Maltais DB, Lepage C, Saulnier J, Crête M, Perron M. Isometric Muscle Strength in Youth Assessed by Hand-Held Dynamometry: A Feasibility, Reliability, and Validity Study A Feasibility, Reliability, and Validity Study. Pediatric Physical Therapy. 2011;23(3):289-99.

59. Schoemaker MM, Niemeijer AS, SMITS ENGELSMAN BC. Feasibility, Reliability, and Validity Study A Feasibility, Reliability, and Validity Study. Pediatric Physical Therapy. 2011;23(3):289-99.

60. Theis J, Gerdhem P, Abbott A. Quality of life outcomes in surgically treated adult scoliosis patients: a systematic review. European spine journal. 2015;24(7):1343-55.

61. Chudyk AM, Jutai JW, Petrella RJ, Speechley M. Systematic review of hip fracture rehabilitation practices in the elderly. Archives of physical medicine and rehabilitation. 2009;90(2):246-62.

62. Beighton P, Solomon L, Soskolne C. Articular mobility in an African population. Annals of the rheumatic diseases. 1973;32(5):413.

63. Shields B, Palermo T, Powers J, Grewe S, Smith G. Predictors of a child’s ability to use a visual analogue scale. Child: care, health and development. 2003;29(4):281-90.

64. Crossley KM, Bennell KL, Cowan SM, Green S. Analysis of outcome measures for persons with patellofemoral pain: which are reliable and valid? Archives of physical medicine and rehabilitation. 2004;85(5):815-22.

65. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs. 1988;14(1):9-17.

66. Garra G, Singer AJ, Taira BR, Chohan J, Cardoz H, Chisena E, et al. Validation of the Wong-Baker FACES pain rating scale in pediatric emergency department patients. Academic Emergency Medicine. 2010;17(1):50-4.

67. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. The Journal of rheumatology. 2010;37(7):1534-41.

68. Nugent J, Ruperto N, Grainger J, Machado C, Sawhney S, Baildam E, et al. The British version of the childhood health assessment questionnaire (CHAQ) and the child health questionnaire (CHQ). Clinical and experimental rheumatology. 2001;19(4; SUPP/23):S163-S7.

69. Hébert LJ, Maltais DB, Lepage C, Saulnier J, Crête M, Perron M. Isometric Muscle Strength in Youth Assessed by Hand-Held Dynamometry: A Feasibility, Reliability, and Validity Study A Feasibility, Reliability, and Validity Study. Pediatric Physical Therapy. 2011;23(3):289-99.

70. Schoemaker MM, Niemeijer AS, SMITS ENGELSMAN BC. Feasibility, Reliability, and Validity Study A Feasibility, Reliability, and Validity Study. Pediatric Physical Therapy. 2011;23(3):289-99.
65. Waters E, Salmon L, Wake M, Hesketh K, Wright M. The Child Health Questionnaire in Australia: reliability, validity and population means. Australian and New Zealand Journal of Public Health. 2000;24(2):207-10.

66. Farrar JT, Young Jr JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-58.

67. Scott W, McCracken LM. Patients’ impression of change following treatment for chronic pain: global, specific, a single dimension, or many? The Journal of Pain. 2015;16(6):518-26.

68. Chan LF, Chow SM, Lo SK. Preliminary validation of the Chinese version of the Pediatric Quality of Life Inventory. International Journal of Rehabilitation Research. 2005;28(3):219-27.

69. Varni JW, Seid M, Smith Knight T, Burwinkle T, Brown J, Szer IS. The PedsQL™ in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory™ Generic Core Scales and Rheumatology Module. Arthritis & Rheumatism. 2002;46(3):714-25.

Figures

![Flow diagram of the study](image)

**Figure 1**

Flow diagram of the study